199 related articles for article (PubMed ID: 17072088)
1. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
Masubuchi Y
Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.
Tettey JN; Maggs JL; Rapeport WG; Pirmohamed M; Park BK
Chem Res Toxicol; 2001 Aug; 14(8):965-74. PubMed ID: 11511170
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone.
Yokoi T
Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
[TBL] [Abstract][Full Text] [Related]
4. Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.
Madsen KG; Grönberg G; Skonberg C; Jurva U; Hansen SH; Olsen J
Chem Res Toxicol; 2008 Oct; 21(10):2035-41. PubMed ID: 18788755
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone thiol adduct formation in human liver microsomes: enzyme kinetics and reaction phenotyping.
Gan J; Qu Q; He B; Shyu WC; Rodrigues AD; He K
Drug Metab Lett; 2008 Aug; 2(3):184-9. PubMed ID: 19356091
[TBL] [Abstract][Full Text] [Related]
6. Identification of glutathione conjugates of troglitazone in human hepatocytes.
Prabhu S; Fackett A; Lloyd S; McClellan HA; Terrell CM; Silber PM; Li AP
Chem Biol Interact; 2002 Nov; 142(1-2):83-97. PubMed ID: 12399157
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.
Lee JK; Marion TL; Abe K; Lim C; Pollock GM; Brouwer KL
J Pharmacol Exp Ther; 2010 Jan; 332(1):26-34. PubMed ID: 19801447
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Saha S; New LS; Ho HK; Chui WK; Chan EC
Toxicol Lett; 2010 Feb; 192(2):141-9. PubMed ID: 19854250
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic rats.
Meechan AJ; Henderson C; Bates CD; Grant MH; Tettey JN
J Pharm Pharmacol; 2006 Oct; 58(10):1359-65. PubMed ID: 17034659
[TBL] [Abstract][Full Text] [Related]
10. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
He K; Talaat RE; Pool WF; Reily MD; Reed JE; Bridges AJ; Woolf TF
Drug Metab Dispos; 2004 Jun; 32(6):639-46. PubMed ID: 15155556
[TBL] [Abstract][Full Text] [Related]
11. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
Kassahun K; Pearson PG; Tang W; McIntosh I; Leung K; Elmore C; Dean D; Wang R; Doss G; Baillie TA
Chem Res Toxicol; 2001 Jan; 14(1):62-70. PubMed ID: 11170509
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone Inhibits Bile Acid Amidation: A Possible Risk Factor for Liver Injury.
Ogimura E; Nakagawa T; Deguchi J; Sekine S; Ito K; Bando K
Toxicol Sci; 2017 Aug; 158(2):347-355. PubMed ID: 28486596
[TBL] [Abstract][Full Text] [Related]
13. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Nozawa T; Sugiura S; Nakajima M; Goto A; Yokoi T; Nezu J; Tsuji A; Tamai I
Drug Metab Dispos; 2004 Mar; 32(3):291-4. PubMed ID: 14977862
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.
Yang K; Brouwer KL
Drug Metab Dispos; 2014 Jul; 42(7):1219-26. PubMed ID: 24799397
[TBL] [Abstract][Full Text] [Related]
15. Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study.
Dixit VA; Bharatam PV
Chem Res Toxicol; 2011 Jul; 24(7):1113-22. PubMed ID: 21657230
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones.
Masubuchi Y; Kano S; Horie T
Toxicology; 2006 May; 222(3):233-9. PubMed ID: 16621215
[TBL] [Abstract][Full Text] [Related]
17. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes.
Saha S; New LS; Ho HK; Chui WK; Chan EC
Toxicol Lett; 2010 Jun; 195(2-3):135-41. PubMed ID: 20307632
[TBL] [Abstract][Full Text] [Related]
18. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.
Yang K; Woodhead JL; Watkins PB; Howell BA; Brouwer KL
Clin Pharmacol Ther; 2014 Nov; 96(5):589-98. PubMed ID: 25068506
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case.
Ikeda T
Drug Metab Pharmacokinet; 2011; 26(1):60-70. PubMed ID: 21178300
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction.
He K; Woolf TF; Kindt EK; Fielder AE; Talaat RE
Biochem Pharmacol; 2001 Jul; 62(2):191-8. PubMed ID: 11389877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
